
ETON Stock Forecast & Price Target
ETON Analyst Ratings
Bulls say
Eton Pharmaceuticals has demonstrated consistent year-over-year revenue growth, with an estimated increase of 20% to $38.1 million in 2024, followed by a remarkable projected growth of 170% to $103.7 million in 2025. The company is also focused on pipeline expansion, with anticipated revenue generation from new products like Amglidia, which is expected to contribute $4.2 million in 2027 and grow to $16.0 million by 2032, contingent upon FDA approval. Furthermore, Eton's management has successfully adjusted revenue expectations based on projected price increases, indicating a positive outlook driven by effective portfolio execution.
Bears say
Eton Pharmaceuticals Inc. is poised to incur a significant financial burden with $30.7 million in upfront payments for the acquisitions of Increlex and Galzin, which may strain its liquidity and operational resources. Additionally, management's belief that these products are priced lower than competing drugs raises concerns about potential revenue and margin challenges in a competitive market. This combination of substantial acquisition costs and pricing pressures creates a negative outlook for the company's financial health and growth potential.
This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
ETON Analyst Forecast & Price Prediction
Start investing in ETON
Order type
Buy in
Order amount
Est. shares
0 shares